DENTSPLY SIRONA Inc (XRAY) Director Michael J. Coleman Sells 9,160 Shares

DENTSPLY SIRONA Inc (NASDAQ:XRAY) Director Michael J. Coleman sold 9,160 shares of the stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $54.90, for a total value of $502,884.00. Following the completion of the sale, the director now directly owns 31,383 shares of the company’s stock, valued at approximately $1,722,926.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of DENTSPLY SIRONA stock opened at $54.87 on Thursday. The company has a market capitalization of $12.84 billion, a P/E ratio of 27.30, a price-to-earnings-growth ratio of 2.04 and a beta of 1.11. DENTSPLY SIRONA Inc has a fifty-two week low of $33.93 and a fifty-two week high of $55.88. The company has a quick ratio of 1.35, a current ratio of 2.06 and a debt-to-equity ratio of 0.33.

DENTSPLY SIRONA (NASDAQ:XRAY) last issued its quarterly earnings data on Friday, May 3rd. The medical instruments supplier reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.10. The company had revenue of $946.20 million during the quarter, compared to analyst estimates of $925.13 million. DENTSPLY SIRONA had a positive return on equity of 8.99% and a negative net margin of 26.48%. The firm’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.45 earnings per share. Equities research analysts predict that DENTSPLY SIRONA Inc will post 2.34 EPS for the current year.

Several equities research analysts recently commented on the company. BidaskClub raised DENTSPLY SIRONA from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Zacks Investment Research raised DENTSPLY SIRONA from a “hold” rating to a “buy” rating and set a $61.00 price target for the company in a report on Saturday, May 11th. Barrington Research raised DENTSPLY SIRONA from a “market perform” rating to an “outperform” rating and set a $63.00 price target for the company in a report on Monday, May 6th. HC Wainwright reaffirmed a “neutral” rating and issued a $55.00 price target (up previously from $49.00) on shares of DENTSPLY SIRONA in a report on Monday, May 6th. Finally, ValuEngine raised DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a report on Saturday, May 4th. Eight analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. DENTSPLY SIRONA has an average rating of “Buy” and an average target price of $53.65.

A number of institutional investors have recently modified their holdings of the stock. Morgan Stanley raised its holdings in DENTSPLY SIRONA by 1,233.9% during the 3rd quarter. Morgan Stanley now owns 5,242,702 shares of the medical instruments supplier’s stock worth $197,860,000 after purchasing an additional 4,849,652 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in DENTSPLY SIRONA by 3.9% during the 4th quarter. State of Alaska Department of Revenue now owns 68,314 shares of the medical instruments supplier’s stock worth $2,540,000 after purchasing an additional 2,594 shares during the last quarter. DNB Asset Management AS raised its holdings in DENTSPLY SIRONA by 1,649.5% during the 4th quarter. DNB Asset Management AS now owns 1,924,560 shares of the medical instruments supplier’s stock worth $71,613,000 after purchasing an additional 1,814,556 shares during the last quarter. Oakbrook Investments LLC grew its position in shares of DENTSPLY SIRONA by 75.5% during the 4th quarter. Oakbrook Investments LLC now owns 22,450 shares of the medical instruments supplier’s stock worth $835,000 after buying an additional 9,660 shares during the period. Finally, Nisa Investment Advisors LLC grew its position in shares of DENTSPLY SIRONA by 15.7% during the 4th quarter. Nisa Investment Advisors LLC now owns 47,797 shares of the medical instruments supplier’s stock worth $1,779,000 after buying an additional 6,500 shares during the period. Institutional investors own 95.83% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.themarketsdaily.com/2019/05/16/dentsply-sirona-inc-xray-director-michael-j-coleman-sells-9160-shares.html.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Featured Article: Portfolio Manager

Insider Buying and Selling by Quarter for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.